A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
Status:
Recruiting
Trial end date:
2023-10-11
Target enrollment:
Participant gender:
Summary
Dry Eye Disease (DED) is a condition where the tear film of the eye becomes unstable and
along with ocular surface inflammation and damage leads to inadequate tear production and eye
lubrication. This study will evaluate symptom relief and tolerability of ABBV-444 eye drops
in adult participants.
ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). This is a 30-day,
open-label study to evaluate adult participant symptoms and tolerability of ABBV-444. Around
40 participants will be enrolled in 1 site in the United States.
Participants will receive 1-2 drops of ABBV-444 in each eye as needed but minimally twice a
day for 30 days.
There may be higher treatment burden for participants in this trial compared to their
standard of care. Participants will attend regular visits during the study at a hospital or
clinic. The effect of the treatment will be checked by medical assessments, checking for side
effects and completing questionnaires.